Biotheryx, Inc. Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
BioTheryX, Inc. is a clinical-stage biotechnology company developing targeted protein degraders for cancer and inflammatory diseases. It pursues first-in-class degraders, including bifunctional degraders and molecular glues, supported by a proprietary PRODEGY platform built on Cereblon-binding expertise. The lead program, BTX-9341, a CDK4/CDK6 degrader, entered Phase 1 in the third quarter of 2024, and the pipeline includes BTX-10908, targeting SOS1 for pan-KRAS mutant cancers, along with PDE4 degraders for inflammatory conditions. Headquartered in San Diego, California, BioTheryX describes itself as a small-to-mid-sized biotechnology company focused on translating protein degradation science into new therapeutic options. In 2023 it formed a collaboration with Incyte to explore cancer and inflammatory disease drugs. A May 2026 press release noted that data from the Phase 1A dose-escalation study of BTX-9341 in combination with fulvestrant for HR+/HER2- breast cancer in patients previously treated with CDK4/6 inhibitors would be presented at the ESMO Breast Cancer Annual Congress in Berlin.